Activation of KCa3.1 by SKA-31 induces arteriolar dilatation and lowers blood pressure in normo- and hypertensive connexin40-deficient mice

British Journal of Pharmacology

Volumn 170, Issue 2, 2013, Pages 293-303

  Radtke, Josephine ^a,e   Schmidt, Kjestine ^a,e   Wulff, Heike ^b   Köhler, Ralf ^c,d   De Wit, Cor ^a,e  

^a UNIVERSITY OF LÜBECK   (Germany)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^d INSTITUTO ARAGONÉS DE CIENCIAS DE LA SALUD   (Spain)

^e DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

2 d thiazol 2 ylamine); Ca 2+ activated K+ channel; endothelium derived hyperpolarizing factor; gap junction; hypertension; microcirculation; myoendothelial coupling; SKA 31 (naphtho 1

Indexed keywords

ANTIHYPERTENSIVE AGENT; CALCIUM ACTIVATED POTASSIUM CHANNEL; CALCIUM ACTIVATED POTASSIUM CHANNEL KCA3.1; CONNEXIN 40; SKA 31; UNCLASSIFIED DRUG; 1 [(2 CHLOROPHENYL)DIPHENYLMETHYL] 1H PYRAZOLE; BENZOTHIAZOLE DERIVATIVE; GAP JUNCTION PROTEIN; INTERMEDIATE CONDUCTANCE CALCIUM ACTIVATED POTASSIUM CHANNEL; KCNN4 PROTEIN, MOUSE; NAPHTHO(1,2 D)THIAZOL 2 YLAMINE; NAPHTHO(1,2-D)THIAZOL-2-YLAMINE; PYRAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTERY DILATATION; ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; GAP JUNCTION; HEART RATE; HYPERPOLARIZATION; HYPERTENSION; IN VIVO STUDY; MEAN ARTERIAL PRESSURE; MICROSCOPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TELEMETRY; WILD TYPE; 2-D]THIAZOL-2-YLAMINE); ANIMAL; BLOOD PRESSURE; CA2+-ACTIVATED K+ CHANNEL; ENDOTHELIUM CELL; ENDOTHELIUM-DERIVED HYPERPOLARIZING FACTOR; GENETICS; GENOTYPE; KNOCKOUT MOUSE; METABOLISM; MICROCIRCULATION; MYOENDOTHELIAL COUPLING; PATHOPHYSIOLOGY; SKA-31 (NAPHTHO[1; VASCULAR ENDOTHELIUM; VASODILATATION;

2-D]THIAZOL-2-YLAMINE); CA2+-ACTIVATED K+ CHANNEL; ENDOTHELIUM-DERIVED HYPERPOLARIZING FACTOR; GAP JUNCTION; HYPERTENSION; MICROCIRCULATION; MYOENDOTHELIAL COUPLING; SKA-31 (NAPHTHO[1;

ANIMALS; BENZOTHIAZOLES; BLOOD PRESSURE; CONNEXINS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; GAP JUNCTIONS; GENOTYPE; HEART RATE; HYPERTENSION; INTERMEDIATE-CONDUCTANCE CALCIUM-ACTIVATED POTASSIUM CHANNELS; MICE; MICE, KNOCKOUT; MICROCIRCULATION; PYRAZOLES; TELEMETRY; VASODILATION;

EID: 84883260008     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12267     Document Type: Article

References (47)

1. Boettcher M, de Wit C, (2011). Distinct endothelium-derived hyperpolarizing factors emerge in vitro and in vivo and are mediated in part via connexin 40-dependent myoendothelial coupling. Hypertension 57: 802-808.
2. Brähler S, Kaistha A, Schmidt VJ, Wölfle SE, Busch C, Kaistha BP, et al. (2009). Genetic deficit of SK3 and IK1 channels disrupts the endothelium-derived hyperpolarizing factor vasodilator pathway and causes hypertension. Circulation 119: 2323-2332.
3. Chadjichristos CE, Scheckenbach KE, van Veen TA, Richani Sarieddine MZ, de Wit C, Yang Z, et al. (2010). Endothelial-specific deletion of connexin40 promotes atherosclerosis by increasing CD73-dependent leukocyte adhesion. Circulation 121: 123-131.
4. Chaytor AT, Bakker LM, Edwards DH, Griffith TM, (2005). Connexin-mimetic peptides dissociate electrotonic EDHF-type signalling via myoendothelial and smooth muscle gap junctions in the rabbit iliac artery. Br J Pharmacol 144: 108-114.
5. Ca2.3 channels produces endothelial hyperpolarisation and lowers blood pressure in conscious dogs. Br J Pharmacol 165: 223-234.
6. Dora KA, Sandow SL, Gallagher NT, Takano H, Rummery NM, Hill CE, et al. (2003). Myoendothelial gap junctions may provide the pathway for EDHF in mouse mesenteric artery. J Vasc Res 40: 480-490.
7. Edwards G, Feletou M, Weston AH, (2010). Endothelium-derived hyperpolarising factors and associated pathways: a synopsis. Pflugers Arch 459: 863-879.
8. Feletou M, Vanhoutte PM, (2009). EDHF: an update. Clin Sci (Lond) 117: 139-155.
9. Garland CJ, Hiley CR, Dora KA, (2011). EDHF: spreading the influence of the endothelium. Br J Pharmacol 164: 839-852.
10. + channels in normal and impaired EDHF-dilator responses-relevance to cardiovascular pathologies and drug discovery. Br J Pharmacol 157: 509-526.
11. Griffith TM, Chaytor AT, Taylor HJ, Giddings BD, Edwards DH, (2002). CAMP facilitates EDHF-type relaxations in conduit arteries by enhancing electrotonic conduction via gap junctions. Proc Natl Acad Sci U S A 99: 6392-6397.
12. Heberlein KR, Straub AC, Isakson BE, (2009). The myoendothelial junction: breaking through the matrix? Microcirculation 16: 307-322.
13. Isakson BE, Duling BR, (2005). Heterocellular contact at the myoendothelial junction influences gap junction organization. Circ Res 97: 44-51.
14. Isakson BE, Kronke G, Kadl A, Leitinger N, Duling BR, (2006). Oxidized phospholipids alter vascular connexin expression, phosphorylation, and heterocellular communication. Arterioscler Thromb Vasc Biol 26: 2216-2221.
15. Isakson BE, Best AK, Duling BR, (2008). Incidence of protein on actin bridges between endothelium and smooth muscle in arterioles demonstrates heterogeneous connexin expression and phosphorylation. Am J Physiol Heart Circ Physiol 294: H2898-H2904.
16. Jobs A, Schmidt K, Schmidt VJ, Lübkemeier I, van Veen TAB, Kurtz A, et al. (2012). Defective Cx40 maintains Cx37 expression but intact Cx40 is crucial for conducted dilations irrespective of hypertension. Hypertension 60: 1422-1429.
17. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). NC3Rs Reporting Guidelines Working Group. Br J Pharmacol 160: 1577-1579.
18. Koeppen M, Feil R, Siegl D, Feil S, Hofmann F, Pohl U, et al. (2004). CGMP-dependent protein kinase mediates NO- but not acetylcholine-induced dilations in resistance vessels in vivo. Hypertension 44: 952-955.
19. Ca-channels as therapeutic targets in hypertension and restenosis disease. Expert Opin Ther Targets 14: 143-155.
20. Ca3.1-deficiency produces locomotor hyperactivity and alterations in cerebral monoamine levels. PloS ONE 7: e47744-e47744.
21. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
22. Mather S, Dora KA, Sandow SL, Winter P, Garland CJ, (2005). Rapid endothelial cell-selective loading of connexin 40 antibody blocks endothelium-derived hyperpolarizing factor dilation in rat small mesenteric arteries. Circ Res 97: 399-407.
23. + channel SK3 and connexin40 in arteriolar dilations during skeletal muscle contraction. FASEB J 24: 3572-3579.
24. Potocnik SJ, McSherry I, Ding H, Murphy TV, Kotecha N, Dora KA, et al. (2009). Endothelium-dependent vasodilation in myogenically active mouse skeletal muscle arterioles: role of EDH and K(+) channels. Microcirculation 16: 377-390.
25. + channel. J Med Chem 41: 2-5.
26. Ca3.1 potassium channels, potentiates the endothelium-derived hyperpolarizing factor response and lowers blood pressure. Mol Pharmacol 75: 281-295.
27. Schmidt K, Dubrovska G, Nielsen G, Fesus G, Uhrenholt TR, Hansen PB, et al. (2010). Amplification of EDHF-type vasodilatations in TRPC1-deficient mice. Br J Pharmacol 161: 1722-1733.
28. Schweda F, Kurtz L, de Wit C, Janssen-Bienhold U, Kurtz A, Wagner C, (2009). Substitution of connexin40 with connexin45 prevents hyperreninemia and attenuates hypertension. Kidney Int 75: 482-489.
29. Ca channels enhance agonist-evoked endothelial nitric oxide synthesis and arteriolar vasodilation. FASEB J 23: 1138-1145.
30. + channel. Circ Res 99: 537-544.
31. Simon AM, McWhorter AR, (2003). Decreased intercellular dye-transfer and downregulation of non-ablated connexins in aortic endothelium deficient in connexin37 or connexin40. J Cell Sci 116: 2223-2236.
32. Ca 3.1 channels maintain endothelium-dependent vasodilatation in isolated perfused kidneys of spontaneously hypertensive rats after chronic inhibition of NOS. Br J Pharmacol 167: 854-867.
33. Sokoya EM, Burns AR, Setiawan CT, Coleman HA, Parkington HC, Tare M, (2006). Evidence for the involvement of myoendothelial gap junctions in EDHF-mediated relaxation in the rat middle cerebral artery. Am J Physiol Heart Circ Physiol 291: H385-H393.
34. Stankevicius E, Dalsgaard T, Kroigaard C, Beck L, Boedtkjer E, Misfeldt MW, et al. (2011). Opening of small and intermediate calcium-activated potassium channels induces relaxation mainly mediated by nitric-oxide release in large arteries and endothelium-derived hyperpolarizing factor in small arteries from rat. J Pharmacol Exp Ther 339: 842-850.
35. + channel subunits form heteromultimers via the coiled-coil domains in the C termini of the channels. Circ Res 107: 851-859.
36. Wagner C, de Wit C, Kurtz L, Grünberger C, Kurtz A, Schweda F, (2007). Connexin40 is essential for the pressure control of renin synthesis and secretion. Circ Res 100: 556-563.
37. Wagner C, Jobs A, Schweda F, Kurtz L, Kurt B, Lopez MLS, et al. (2010). Selective deletion of connexin 40 in renin-producing cells impairs renal baroreceptor function and is associated with arterial hypertension. Kidney Int 78: 762-768.
38. de Wit C, (2004). Connexins pave the way for vascular communication. News Physiol Sci 19: 148-153.
39. de Wit C, (2010). Different pathways with distinct properties conduct dilations in the microcirculation in vivo. Cardiovasc Res 85: 604-613.
40. de Wit C, Griffith TM, (2010). Connexins and gap junctions in the EDHF phenomenon and conducted vasomotor responses. Pflugers Arch 459: 897-914.
41. de Wit C, Wölfle SE, (2007). EDHF and gap junctions: important regulators of vascular tone within the microcirculation. Curr Pharm Biotechnol 8: 11-25.
42. de Wit C, Roos F, Bolz SS, Kirchhoff S, Krüger O, Willecke K, et al. (2000). Impaired conduction of vasodilation along arterioles in connexin40 deficient mice. Circ Res 86: 649-655.
43. de Wit C, Roos F, Bolz SS, Pohl U, (2003). Lack of vascular connexin 40 is associated with hypertension and irregular arteriolar vasomotion. Physiol Genomics 13: 169-177.
44. Wölfle SE, de Wit C, (2005). Intact endothelium-dependent dilation and conducted responses in resistance vessels of hypercholesterolemic mice in vivo. J Vasc Res 42: 475-482.
45. Ca3.1 in endothelium-derived hyperpolarizing factor-type dilations and conducted responses in the microcirculation in vivo. Cardiovasc Res 82: 476-483.
46. Ca1: a potential immunosuppressant. Proc Natl Acad Sci U S A 97: 8151-8156.
47. + channel in atrioventricular nodes. Circ Res 102: 465-471.